Jolanda Howe Sells 842 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 842 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $80,991.98. Following the transaction, the senior vice president directly owned 3,700 shares in the company, valued at approximately $355,903. The trade was a 18.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $86,423.58.

Mirum Pharmaceuticals Trading Up 1.6%

Shares of Mirum Pharmaceuticals stock opened at $100.85 on Thursday. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $101.50. The firm’s 50 day simple moving average is $78.97 and its two-hundred day simple moving average is $71.75. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of -117.27 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same period last year, the business posted ($0.30) earnings per share. The company’s revenue for the quarter was up 47.1% compared to the same quarter last year. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. JMP Securities set a $95.00 price target on Mirum Pharmaceuticals in a report on Wednesday, November 5th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Citizens Jmp boosted their price objective on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, December 19th. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $104.92.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long‑term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52‑Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer‑range estimates — mixed guidance that tempers but does not negate the bullish long‑term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ≈$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near‑term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. MCF Advisors LLC raised its holdings in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the period. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals during the third quarter worth about $33,000. Comerica Bank boosted its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. Quarry LP acquired a new position in Mirum Pharmaceuticals in the 3rd quarter valued at about $41,000. Finally, CWM LLC increased its holdings in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after buying an additional 161 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.